Table 2.

Meta-analysis of NGS data and Sanger sequencing data of BP patients and controls.

mtSNP	Gene/region	Sequencing method	Group	Sequenced (n)	Variant carrier (n)	Frequency (%)	Odds ratio (95% CI)	P-value*	Q (p adjust, Hommel)
m.16263 T>C	D-loop	NGS	BP	180	1	0.56	0.1116 (0.0051–0.7471)	0.0201
			Control	188	9	4.79
		Sanger	BP	82	0	0.00	0 (0–1.2049)	0.1222
			Control	90	4	4.44
		Meta-analysis	BP	262	1	0.38	0.1833 (0.0635–0.5293)	0.0017	0.0085
			Control	278	13	4.68
m.11914G>A	MT-ND4	NGS	BP	180	6	3.33	6.4216 (0.8682–146.8755)	0.0626
			Control	188	1	0.53
		Sanger	BP	89	4	4.49	4.7190 (0.6014-−116.3248)	0.1860
			Control	102	1	0.98
		Meta-analysis	BP	269	10	3.72	4.2418 (1.3521–13.3077)	0.0132	0.0264
			Control	290	2	0.69
m.15904C>T	MT-TT	NGS	BP	180	9	5.00	3.2360 (0.876–14.143)	0.0813
			Control	188	3	1.60
		Sanger	BP	88	4	4.55	0.7867 (0.2019–3.0665)	0.7574
			Control	104	6	5.77
		Meta-analysis	BP	268	13	4.85	1.6283 (0.6935–3.8232)	0.2629	0.2629
			Control	292	9	3.08
m.16051A>G	D-loop	NGS	BP	180	2	1.11	0.6936 (0.0852–4.5071)	1
			Control	188	3	1.60
		Sanger	BP	88	0	0.00	0 (0–0.5505)	0.0041
			Control	104	9	8.65
		Meta-analysis	BP	268	2	0.75	0.2583 (0.0889–0.7505)	0.0129	0.0258
			Control	292	12	4.11
m.16162 A>G	D-loop	NGS	BP	180	2	1.11	0.4121 (0.0574–2.0169)	0.4494
			Control	188	5	2.66
		Sanger	BP	88	0	0.00	0 (0–0.6679)	0.0081
			Control	104	8	7.69
		Meta-analysis	BP	268	2	0.75	0.2464 (0.0881–0.6889)	0.0076	0.0198
			Control	292	13	4.45

For the Sanger sequencing, 106 controls (for the genotyping of m.15904C>T, m.16051A>G, m.16162A>G, and m.16263T>C) or 104 controls (for the genotyping of m.11914G>A) and 90 BP samples were tested. The number of samples with no genotyping data due to the low quality-sequence was subtracted from the tested sample number.